CNSP Insider Trading Activity and SEC Form 4 Filings
CNSP insider trading summary
Over the past 12 months, insiders at CNS Pharmaceuticals, Inc. (CNSP) reported 2 open-market purchases worth $44K by 2 insiders and no sales on SEC Form 4. Net insider buying was $44K.
Latest CNSP insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| May 18, 2026 | Michal Fisher | Director | Buy | $10K (2,000 @ $5.00) |
| May 18, 2026 | Faith L. Charles | Director | Buy | $34K (7,100 @ $4.79) |
| Feb 1, 2024 | John M Climaco | Chief Executive Officer | Buy | $50K (166,666 @ $0.30) |
| Feb 1, 2024 | Carl Anthony Evans | Director | Buy | $10K (33,333 @ $0.30) |
| Feb 1, 2024 | Christopher Downs | Chief Financial Officer | Buy | $20K (66,666 @ $0.30) |
| Feb 1, 2024 | Jerzy Gumulka | Director | Buy | $10K (33,333 @ $0.30) |
| Aug 22, 2023 | Christopher Downs | Chief Financial Officer | Buy | $34K (27,000 @ $1.27) |
| Aug 16, 2023 | John M Climaco | Chief Executive Officer | Buy | $5K (2,750 @ $1.80) |
| Apr 19, 2023 | Jerzy Gumulka | Director | Buy | $4K (2,500 @ $1.70) |
| Apr 17, 2023 | Christopher Downs | Chief Financial Officer | Buy | $10K (3,100 @ $3.20) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.